Radiopharmaceuticals for WBAMC

The purpose of this sources sought notice is to conduct market research to determine if responsible sources exist by determining if this effort can be successfully competed and/or set-aside for Small Businesses. The proposed North American Industry Classification System (NAICS) Code is 325412 – Pharmaceutical Preparation Manufacturing, 1,300 employees. The Government will use this information to determine the best acquisition strategy for this procurement. The Government is interested in all large and small businesses to include 8(a), Service-Disabled Veteran-Owned, HubZone, and Women-Owned small business concerns.

The Medical Readiness Contracting Office-West (MRCO-W), Fort Bliss, Texas, is seeking potential sources to establish a radiopharmaceuticals contract for the Department of Nuclear Medicine at William Beaumont Army Medical Center (WBAMC), Fort Bliss, Texas.

This requirement is for the purchase of:

DAT SCAN (Ioflupane I123) - This radio pharmaceutical used to diagnose Parkison disease.

INDIUM OXINE-This radio pharmaceutical combined with a patient’s white blood cells used to diagnose infections of unknown origins.

CERETEC KIT - This cold kit when combined with radioactive Tc99m under sterile compounding forms a radio pharmaceutical used to diagnose brain disorders dementia and evaluated a patient for brain death. Also combined with radioactive Tc99m and a patient’s white blood cells can look for infections of unknown origins.

ADREVIEW - This radio pharmaceutical used to diagnose pheochromocytoma or neuroblastoma (types of tumors)

INDIUM DTPA IN-111 - This radio pharmaceutical used to diagnose spinal cord leaks and swelling in the brain is delivered through an injection directly into the spinal canal by a board-certified physician.

Period of Performance: 1 October 2025 - 30 September 2026.

This is not a solicitation. This information is for planning purposes only and is not to be construed as a commitment by the government, implied or otherwise, to issue a solicitation or award a contract. Contractors responding to this sources-sought notice are advised their response does not ensure participation in future solicitations or contract awards. The government will not reimburse any company or individual for any expense associated with preparation or participation in this research. Interested parties should e-mail responses to troy.a.loge.civ@health.mil.